Sample issue — this is a real, complete edition of the monthly report Cost Tracker members receive by email. Members also get a Cheapest Path sheet personalized to their medication and insurance situation, plus same-week alerts between issues.
GLP-1 Cost & Coverage Report — July 2026
All prices and rules below were verified directly on the official source pages on July 12–13, 2026. Things change fast in this market — that's the point of this report.
The month in 60 seconds
- Medicare now covers weight-loss GLP-1s for the first time — $50/month. The GLP-1 Bridge program started July 1. But only specific product formats qualify, and the eligibility rules have sharp edges (details below).
- Massachusetts quietly ended Medicaid coverage of weight-loss-only GLP-1s on July 1. About 22,000 MassHealth members are affected. Most published "which states cover GLP-1s" lists haven't caught this yet.
- A $149/month price cliff is coming August 31 for the Wegovy 4mg pill self-pay offer — it reverts to $199 after that.
- The FDA's decision on compounded GLP-1s is still pending. The comment period closed at the end of June; a final determination could land any week and would formally end large-scale compounding of semaglutide and tirzepatide.
- Cheapest brand-name entry points right now: Foundayo pill at $149/month cash, Wegovy pill at $149/month cash (1.5mg and 4mg), or $25/month with commercial insurance copay cards. On Medicare with the Bridge: $50/month.
What changed in July
Medicare's GLP-1 Bridge is live: $50/month — here's the fine print
Since July 1, eligible Medicare patients pay a $50 copay for a one-month supply of covered weight-loss GLP-1s. Verified directly on Medicare.gov (July 12, 2026):
Covered products: Foundayo (tablet) · Wegovy (injection or tablet) · Zepbound: KwikPen ONLY — single-dose vials and other pen formats are NOT covered. If your doctor writes "Zepbound" without specifying KwikPen, expect a denial at the pharmacy counter.
Who qualifies (age 18+, and not already covered for GLP-1s through your Part D plan):
| Your BMI | You also need |
|---|---|
| 35 or higher | Nothing else |
| 30–34.9 | One of: diastolic heart failure (HFpEF), uncontrolled hypertension, chronic kidney disease (stage 3a+), prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease |
| 27–29.9 | One of: prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease |
Not eligible if your diagnosis is type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease alone — though your Part D plan may separately cover GLP-1s for those conditions.
The program ends December 31, 2027. Prior authorizations (including refills and dose changes) run through that date unless you switch drugs. If you're eligible, the clock on cheap access is already running.
Massachusetts dropped weight-loss GLP-1 coverage from Medicaid
Effective July 1, MassHealth ended coverage of GLP-1s prescribed solely for weight loss (source: mass.gov, verified July 13, 2026). Roughly 22,000 members — including about 2,500 children — lost that coverage. A narrower medical-necessity path remains for cardiovascular disease, MASH, or moderate-to-severe sleep apnea.
Why this matters beyond Massachusetts: the widely cited count of "13 states cover GLP-1s for obesity under Medicaid" (KFF, January 2026) is now overstated. State Medicaid coverage is eroding faster than the published trackers update. If you're on Medicaid and using a GLP-1 for weight loss, your state's status is worth re-checking every month — it's checked in every issue of this report.
Compounded GLP-1s: the final door hasn't closed yet, but it's closing
The FDA has proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the formal end of mass compounding. The comment period closed at the end of June; as of July 13 there is no final determination yet. We check the FDA newsroom and Federal Register twice a week and will flag the decision the week it lands. (Detail we caught that illustrates how messy this is: FDA's press release and its own Federal Register notice state comment deadlines one day apart — June 29 vs. June 30.)
Current prices — every channel (verified July 12, 2026)
| Drug & form | Cash/self-pay | With commercial insurance | Medicare (Bridge) | The catch |
|---|---|---|---|---|
| Wegovy pen | $199/mo intro (first 2 fills, 0.25/0.5mg only, thru Dec 31) → then $349/mo; 7.2mg HD $399/mo | As little as $25/mo (savings card, max benefit $100/mo) | $50/mo | Intro price requires being new to the savings program |
| Wegovy pill | $149/mo (1.5mg and 4mg) | As little as $25/mo | $50/mo | 4mg offer ends Aug 31 → $199/mo |
| Ozempic pen | $199/mo intro (first 2 fills) → $349/mo (0.25–1mg) or $499/mo (2mg) | As little as $25/mo (up to 3-month fills) | — (diabetes coverage via Part D separate) | Intro offer thru Dec 31 |
| Ozempic pill | $149/mo (1.5mg) new patients; $199 (4mg) / $299 (9mg) existing | As little as $25/mo | — | Tier depends on dose and patient status |
| Zepbound (vial or KwikPen) | $299 (2.5mg) / $399 (5mg) / $499 (7.5mg) / $699 (10–15mg) | Single-dose pen from $25/mo (copay card) | $50/mo — KwikPen only | Higher tiers discount to $449 ONLY if you refill within 45 days — miss the window, pay $499–699 |
| Foundayo pill | $149/mo (0.8mg); $199 (2.5mg); $299 (higher doses) | As little as $25/mo (card expires Dec 31, 2026; $1,000 annual cap) | $50/mo | Higher-dose pricing sits in the fine print, not the headline |
| GoodRx route | Wegovy tablets $149/mo; Zepbound $995/mo — avoid | — | — | For Zepbound, GoodRx is ~2–3x Lilly's own direct price right now |
Deadlines to know
| Date | What happens | Who should care |
|---|---|---|
| Aug 31, 2026 | Wegovy 4mg pill self-pay offer ends → $199/mo | Cash-pay pill users: a fill before the deadline locks one more month at $149 |
| Any week now | FDA final 503B determination could land | Anyone still using compounded semaglutide/tirzepatide — have your exit plan ready |
| Dec 31, 2026 | Wegovy & Ozempic pen intro offers ($199 first fills) end; Foundayo savings card expires | New starters and commercially insured Foundayo users |
| Dec 31, 2027 | Medicare GLP-1 Bridge program ends | Every Medicare member using the $50 benefit — this is temporary |
What to do, by situation
On Medicare: check the Bridge eligibility table above. If you qualify, ask your prescriber now — and if it's Zepbound, the script must say KwikPen. The program is temporary; every month of delay is a month of the benefit gone.
On Medicaid: verify your state still covers weight-loss GLP-1s before your next refill — Massachusetts just proved the lists go stale. If your state dropped coverage, the cash-pay pill options ($149) are the usual fallback, and the medical-necessity carve-outs (heart disease, MASH, sleep apnea) may still apply to you — ask your prescriber.
Commercial insurance, drug covered: you should be at or near $25/month with the manufacturer savings card. Paying more? The card, not the pharmacy counter price, is usually the fix.
Commercial insurance, drug excluded or denied: most denials have an appeal path (members get our appeal templates). While appealing, the cash-pay pill prices beat abandoning treatment.
Paying cash: the pills are the value play right now — Foundayo or Wegovy pill at $149/month versus $349–699 for injectables. If you're on Zepbound higher doses, the 45-day refill window is worth a calendar reminder: missing it costs $50–250/month.
Sources & verification
Every figure above was read directly from the official source on the date shown: wegovy.com, ozempic.com, zepbound.lilly.com, pricinginfo.lilly.com, foundayo.lilly.com, medicare.gov, mass.gov, goodrx.com, kff.org, fda.gov, and the Federal Register. Nothing in this report is estimated, remembered, or taken from third-party articles. Where something couldn't be verified, we say so rather than guess.
The GLP-1 Cost Tracker is an educational service from GLP-1 Answers, an independent health education resource. Nothing here is medical, legal, or insurance advice; medication decisions belong with you and your prescriber. Prices and coverage terms can change without notice — confirm directly with the program, plan, or pharmacy before making decisions. We take no money from manufacturers, pharmacies, insurers, or providers.